Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer
Advanced Prostate Cancer Consensus Conference shared on LinkedIn:
“Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer out on Nature Medicine.
Trial analyzed circulating tumor DNA and germline DNA in patients randomized to receive androgen receptor pathway inhibitors (ARPIs), taxanes, or physician’s choice of treatment.
The primary endpoint, time to no longer clinically benefitting (NLCB), was met after 218 randomizations. ARPIs showed significantly longer time to NLCB (11.1 months) and overall survival (38.7 months) compared to taxanes and physician’s choice treatments.
Biomarker analysis revealed that ARPIs were especially effective in AR-negative, TP53 wild-type, and TMPRSS2–ERG fusion-positive patients.”
Source: Advanced Prostate Cancer Consensus Conference/LinkedIn
Authors: Bram De Laere, Alessio Crippa, Andrea Discacciati, Berit Larsson, Maria Persson, Susanne Johansson, Sanne D’hondt, R. Bergström, Venkatesh Chellappa, Markus Mayrhofer, Mahsan Banijamali, Anastasijia Kotsalaynen, Céline Schelstraete, Jan Pieter Vanwelkenhuyzen, Marie Hjälm-Eriksson, Linn Pettersson, Anders Ullén, Nicolaas Lumen, Gunilla Enblad, Camilla Thellenberg Karlsson, Elin Jänes, Johan Sandzén, Peter Schatteman, Maria Nyre Vigmostad, Martha Olsson, Christophe Ghysel, Brieuc Sautois, Wendy De Roock, Siska Van Bruwaene, Mats Anden, Ingrida Verbiene, Daan De Maeseneer, Els Everaert, Jochen Darras, Bjørg Y. Aksnessether, Daisy Luyten, Michiel Strijbos, Ashkan Mortezavi, Jan Oldenburg, Piet Ost, Martin Eklund, Henrik Grönberg and Johan Lindberg.
